SCHEMBL2422099

SCHEMBL2422099

O=C(NCc1ccc(S(=O)(=O)N2CCN(C(=O)c3ccco3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.59
▸ PKM P14618 3/20 0.59
▸ HPGD P15428 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ RECQL P46063 1/20 0.55
▸ MAPK9 P45984 1/20 0.55
▸ MAPK10 P53779 1/20 0.55
▸ GAA P10253 1/20 0.54
▸ POLB P06746 2/20 0.53
▸ ALOX12 P18054 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ CYP2C9 P11712 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ NPSR1 Q6W5P4 1/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ LMNA P02545 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894669 0.89 MAPK9 (0.59) ALDH1A1MAPK9MAPK10POLBMEN1
SCHEMBL2420177 0.87 MAPK9 (0.60) ALDH1A1PKMMAPK9MAPK10POLB
SCHEMBL2424777 0.86 MAPK9 (0.57) ALDH1A1PKMHPGDHSD17B10MAPK9
SCHEMBL6431701 0.85 MAPK9 (0.59) ALDH1A1PKMMAPK9MAPK10POLB
SCHEMBL7894704 0.84 MAPK9 (0.55) ALDH1A1MAPK9MAPK10POLBMEN1
SCHEMBL7894689 0.84 MAPK9 (0.55) ALDH1A1MAPK9MAPK10POLBMEN1
SCHEMBL3479850 0.84 MAPK9 (0.55) ALDH1A1PKMMAPK9MAPK10GAA
SCHEMBL3480236 0.84 MAPK9 (0.57) ALDH1A1PKMMAPK9MAPK10GAA
SCHEMBL27493937 0.83 MAPK9 (0.54) ALDH1A1MAPK9MAPK10POLBMEN1
SCHEMBL3480648 0.83 MAPK9 (0.60) ALDH1A1MAPK9MAPK10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 — — US claimed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 — — US claimed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 — — EP claimed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 — — CN claimed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 — — CN claimed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP claimed
US-8658640-B2 JNK inhibitors for the treatment of endometriosis MERCK SERONO SA (CH) 2014-02-25 — — US disclosed
US-8592414-B2 JNK inhibitors for the treatment of endometriosis Merck Serono, S.A. (CH) 2013-11-26 — — US disclosed
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-24 — — US disclosed
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-10 — — US disclosed
US-8012995-B1 Pharmaceutically active sulfonamide derivatives MERCK SERONO SA (CH) 2011-09-06 — — US disclosed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 — — US disclosed
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases LABORATOIRES SERONO SA (CH) 2009-07-09 — — US disclosed
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2008-02-14 — — US disclosed
CN-1960726-A Composition comprising a jnk inhibitor and cyclosporin APPLIED RESEARCH SYSTEMS (AN) 2007-05-09 — — CN disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 — — US disclosed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 — — EP disclosed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 — — CN disclosed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 — — CN disclosed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases MAPKAPK2, JUN, MAP3K13 ALDH1A1 3736/4885PKM 2126/4885HPGD 1617/4885
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS ALDH1A1 3588/4885PKM 2329/4885HPGD 3686/4885
US-20080039377-A1 Composition Comprising a Jnk Inhibitor and Cyclosporin LCK, MAPKAPK2, MAP3K20 ALDH1A1 4785/4885PKM 2710/4885HPGD 3719/4885
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN ALDH1A1 3264/4885PKM 1872/4885HPGD 1135/4885
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN ALDH1A1 3264/4885PKM 1872/4885HPGD 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback